Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.
Elite Pharmaceuticals, Inc. develops, manufactures, and distributes niche generic pharmaceutical products, with product lines focused on immediate-release and controlled-release solid oral dose products. Company news commonly covers FDA approvals for abbreviated new drug applications, commercial launches under the Elite Laboratories label, and licensed distribution relationships with third-party pharmaceutical marketing organizations.
Recurring updates also include quarterly financial results, conference-call announcements, and operating commentary tied to generic product sales. Recent company developments have included methadone hydrochloride tablets, ropinirole extended-release tablets, lisdexamfetamine products, and naltrexone products within Elite's generic drug portfolio.
Elite Pharmaceuticals reported its financial results for the first quarter of fiscal year 2021, ending June 30, 2020. The company achieved consolidated revenues of $7.5 million, reflecting a significant 124% increase compared to the same period last year. This growth was driven primarily by the sales of generic extended release Adderall and increased sales of other generic medications. A conference call will be held on August 17, 2020, to discuss these results and recent business developments.
Elite Pharmaceuticals (OTCQB:ELTP) will release its fiscal Q1 2021 financial results on August 14, 2020, followed by a live conference call on August 17, 2020, at 11:30 AM EDT. The company specializes in developing niche generic products, including oral, controlled-release drugs. Stockholders are encouraged to submit questions ahead of the call. Elite operates a GMP facility in Northvale, NJ and has partnerships with TAGI Pharma, Glenmark Pharmaceuticals, and Lannett Company.